2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.15 Lu

PP01.15 Lu - Abstract

Pdf Summary

This study explores the diversity of BRAF mutations in Non-Small Cell Lung Cancer (NSCLC) and its implications for treatment. The research involved analyzing a cohort of 97 patients with BRAF-mutant NSCLC, categorizing the mutations into three classes, conducting computational modeling of the BRAF oncogene, and performing chemical and genetic screens of different mutation classes. Results showed that patients with class I BRAF mutations who received combination BRAF and MEK inhibitor therapy had better overall survival compared to those without targeted treatment. Class II mutations were associated with concurrent MAPK alterations and responded to various inhibitors, while class III mutations exhibited insensitivity to BRAF inhibitors due to steric hindrance. The study concludes that BRAF variants have distinct functional and therapeutic implications, emphasizing the importance of personalized treatment approaches based on specific mutation classes. Further research is needed to determine the clinical value of inhibiting EGFR, ERK, MEK, and pan-RAF in class II and III patients to enhance treatment outcomes in NSCLC.

Keywords

BRAF mutations

Non-Small Cell Lung Cancer

NSCLC treatment

class I mutations

class II mutations

class III mutations

BRAF and MEK inhibitor therapy

MAPK alterations

personalized treatment approaches

EGFR inhibition